Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome

Ann Hematol. 2020 Mar;99(3):661-662. doi: 10.1007/s00277-020-03940-8. Epub 2020 Jan 31.

Gonzalo De Luna^{1

2}, Luc Darnige^{2

3

4}, Stéphane Roueff⁵, Thierry Peyrard^{6

7}, Jacques Pouchot^{1

2}, Jean-Benoît Arlet^{8

9

10

11}

¹ Internal Medicine Department, Sickle Cell Referral Center, Georges Pompidou European Hospital, AP-HP, Paris, France.
² Université de Paris, Paris, France.
³ Service d'Hématologie Biologique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
⁴ INSERM UMR-S1140, Paris, France.
⁵ Nephrology Department, Georges Pompidou European Hospital, AP-HP, INSERM, Paris, France.
⁶ Département Centre National de Référence pour les Groupes Sanguins (CNRGS), Institut National de la Transfusion Sanguine (INTS), 75011, Paris, France.
⁷ Laboratory of Excellence GR-Ex, Paris, France.
⁸ Internal Medicine Department, Sickle Cell Referral Center, Georges Pompidou European Hospital, AP-HP, Paris, France. jean-benoit.arlet@aphp.fr.
⁹ Université de Paris, Paris, France. jean-benoit.arlet@aphp.fr.
¹⁰ Laboratory of Excellence GR-Ex, Paris, France. jean-benoit.arlet@aphp.fr.
¹¹ Service de Médecine Interne, Hôpital européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France. jean-benoit.arlet@aphp.fr.

No abstract available

Publication types